Background: Recent expiry of patents for tumor necrosis factor (TNF)-α inhibitors has led to
the employment of biosimilars in clinical practice. The aim of the study was to identify any …

Background Anti-tumor necrosis factor-alpha was regarded as an option in treatment of non-
infectious uveitis. However, few studies in the far easter region have concentrated on this …

Background Behçet disease (BD) is a chronic inflammatory systemic disease that affects
skin mucosa, joints, eyes, and blood vessels. Behçet disease shows some clinical …

Purpose: Anti-tumour necrosis factor-alpha (TNF-α) agents are often used for Behçet's
disease (BD) in clinical practice, but they have not been validated by a high level of …

Objectives: Describe the pathophysiology of Behcet disease. Review the presentation of a
patient with Behcet disease. Outline the management options available for Behcet disease …

The arena of uveitis deals with a number of entities, which can be infectious or immune
mediated. Noninfectious uveitis (NIU) has been managed with corticosteroids and …

Prospective and controlled studies for the management of major organ involvement in
Behçet's disease are still limited. Data from primarily retrospective studies confirmed better …

Introduction: Behçet's disease uveitis (BDU) is a potentially blinding disorder. Systemic
treatment with disease-modifying anti-rheumatic drugs (DMARDs) is mandatory in patients …

To identify clinical variables capable of predicting long-term treatment duration of TNF-α
inhibition in patients with Behçet's disease (BD)-related uveitis. Demographic, clinical, and …

Purpose To investigate the role of ultra-widefield fluorescein angiography (UWFA) for
monitoring therapeutic response to adalimumab in patients with Behcet's uveitis. Methods …